BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
how to stratify patients into the highest risk. But we may not be capturing all the patients that are actually high risk and do need treatment in the adjuvant setting. So I really like that part of the Tembola trial and then following them and seeing they convert you know, how many of them converted with treatment, and then how did they do with the tezolizumab treatment.
0
💬
0
Comments
Log in to comment.
There are no comments yet.